Navigation Links
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
Date:11/7/2013

naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 development as a once- daily, oral tablet for the treatment of opioid-induced constipation. For naloxegol, the MAA in Europe and the NDS in Canada have been accepted for filing, and an NDA has been submitted for filing in the U.S. This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid. NKTR-181, a novel mu-opioid analgesic molecule for chronic pain conditions, has completed Phase 2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a novel mu-opioid analgesic molecule in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in a number of Phase 2 studies. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare to treat patients with Gram-negative pneumonia.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 3 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Cautionary Note Regarding Forward-Looking StatementsThis press release contains
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... June 02, 2015 Research and Markets ( http://www.researchandmarkets.com/research/g5r2nj/surgical_incision ... Closures - Global Strategic Business Report" report to their ... the US, Canada , Japan ... , Latin America , and Rest ... for Surgical Incision Closures in US$ Million by the following ...
(Date:6/2/2015)... 2, 2015 Intarcia Therapeutics, Inc. ... from its recently announced synthetic royalty / equity convert ... Investors have purchased Convertible Limited Recourse Notes from Intarcia ... 2.0% of any future global net sales of ITCA ... Investors also have the option, commencing upon U.S. regulatory ...
(Date:6/2/2015)... 2, 2015 Stoltenberg Consulting , ... today announced the celebration of its 20-year anniversary ... U.S., since its inception in 1995. ... in the healthcare technology industry continues, we strive ... dedication to facilitating clients, organizational goals, understanding that ...
Breaking Medicine Technology:Surgical Incision Closures - Global Strategic Business Report 2015 2Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 2Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 3Stoltenberg Consulting celebrates 20 years of healthcare IT consulting service 2Stoltenberg Consulting celebrates 20 years of healthcare IT consulting service 3
... JOLLA, Calif., Oct. 21 Transdel Pharmaceuticals, Inc. (OTC ... company focused on developing topically administered products using its ... John N. Bonfiglio, Ph.D. as Chief Executive Officer and ... on Transdel,s Board of Directors. With over ...
... the world,s leading research and advisory firms for pharmaceutical and ... drug market will remain relatively flat, increasing from $2.8 billion ... States, France, Germany, Italy, Spain, United Kingdom and Japan. ... Epilepsy forecast a decline in overall sales through ...
Cached Medicine Technology:Transdel Pharmaceuticals Appoints John N. Bonfiglio, Ph.D. as Chief Executive Officer and President 2Transdel Pharmaceuticals Appoints John N. Bonfiglio, Ph.D. as Chief Executive Officer and President 3The Epilepsy Drug Market Will Remain Relatively Flat Through 2019 as Generic Erosion, Especially Within the Second-Generation Antiepileptic Drug Class, is Offset by the Launch of New Therapies 2
(Date:6/2/2015)... Angeles, CA (PRWEB) June 02, 2015 Highly ... have unveiled a plan to drive prolific change in the ... the TDC Team Dental Clinic offers a full ... an expert management structure for dental tourism. , Partnered with ... care team is committed to advancing dentistry and has earned ...
(Date:6/2/2015)... The term “Augmented Reality” was coined ... on the real world. Since then many promising technologies ... a map of the vasculature on the surface of ... , AccuVein, the leader in vein visualization, exemplifies this ... and such widespread adoption of its AccuVein AV400 devices ...
(Date:6/2/2015)... Radaris ” was featured on NewsWatch as part of its ... coolest applications on the market for iOS, Android, and Windows. ... the app review and shared with viewers can help users ... According to Psychology Today, humans are a curious species by ... is a part of human development. People are using the ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 MedPro Healthcare ... services to healthcare facilities, today announced the worldwide release ... effective mobile tool to help candidates find best jobs ... survey released in 2014, 9 in 10 job seekers ... their job search. , The MedPro Top Jobs app ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 ZOOM+, the ... ZOOM+ Performance Health Insurance, announced today the opening of ... White 57 - a three-in-one complete dental exam, cleaning ... Jr. for kids. Like all ZOOM+ services, ZOOM+Smile can ... “Why shouldn’t the dentist office be as inviting as ...
Breaking Medicine News(10 mins):Health News:Team Dental Clinic Unveils Plan to Drive Change in the Dental Tourism Industry 2Health News:Team Dental Clinic Unveils Plan to Drive Change in the Dental Tourism Industry 3Health News:Vein Visualization Emerges as Premier Augmented Reality Application 2Health News:A Comprehensive People Search Application Was Featured on NewsWatch Television 2Health News:MedPro Healthcare Staffing Launches New MedPro Top Jobs App To Facilitate Job Search For Healthcare Professionals 2Health News:ZOOM+ Opens Its First On-Demand ZOOM+Smile Studio and Reinvents the Dental Exam 2
... economic downturn has exacerbated a global food crisis that ... the number of people who are malnourished. The ... three-day workshop to explore the implications of the food ... the effects of the economic crisis and escalating food ...
... ANGELES, July 7 NEUTROGENA(R), the #1 dermatologist recommended ... Sweepstakes, where one lucky grand-prize winner will win an ... the Fresh Faces of Music VIP Event. At the ... of NEUTROGENA(R) will listen to great music, have an ...
... Cystic Fibrosis Foundation announced today that all 50 states plus ... newborns be screened for cystic fibrosis (CF) by the year ... a life-threatening, genetic disease, can have a dramatic impact on ... , Newborn screening for CF was adopted nationwide at a ...
... Foods Market (Nasdaq: WFMI ), the leading ... the Non-GMO Project - a non-profit collaboration of manufacturers, ... to use the Non-GMO,s Product Verification Program (PVP) in ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20090707/DA42720 ) , ...
... PALO ALTO, Calif., July 7, 2009 Jazz Pharmaceuticals, Inc. (Nasdaq: ... a private placement of an aggregate of 1,895,734 units, comprised of ... purchase up to 947,867 additional shares of common stock for aggregate ... price for a share of common stock and a warrant to ...
... July 7 Wound Care Innovations, LLC, a subsidiary ... it will exhibit at the New Cardiovascular Horizons and ... conference in New Orleans July 9-11. , ... the country, bringing together cardiologists, surgeons, podiatrists, wound care ...
Cached Medicine News:Health News:NEUTROGENA(R) Announces Fresh Faces Sweepstakes 2Health News:All Fifty States to Screen Newborns for Cystic Fibrosis by 2010 2Health News:Whole Foods Market(R) Partners With Non-GMO Project to Label Company's Private Label Food Products Using New Third-Party Standard 2Health News:Whole Foods Market(R) Partners With Non-GMO Project to Label Company's Private Label Food Products Using New Third-Party Standard 3Health News:Whole Foods Market(R) Partners With Non-GMO Project to Label Company's Private Label Food Products Using New Third-Party Standard 4Health News:Jazz Pharmaceuticals Completes $7 Million Private Placement 2Health News:Wound Management Technologies, Inc Announces Conference Plans and Presentations on Advanced Wound Care Product 2Health News:Wound Management Technologies, Inc Announces Conference Plans and Presentations on Advanced Wound Care Product 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: